The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas
Open accessAbstract
Genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to dramatically alter the landscape of the coronavirus disease 2019 (COVID-19) pandemic. The recently described variant of concern designated Omicron (B.1.1.529) has rapidly spread worldwide and is now responsible for the majority of COVID-19 cases in many countries. Because Omicron was recognized recently, many knowledge gaps exist about its epidemiology, clinical severity, and disease course. A genome sequencing study of SARS-CoV-2 in the Houston Methodist health care system identified 4468 symptomatic patients with infections caused by Omicron from late November 2021 through January 5, 2022. Omicron rapidly increased in only 3 weeks to cause 90% of all new COVID-19 cases, and at the end of the study period caused 98% of new cases. Compared with patients infected with either Alpha or Delta variants in our health care system, Omicron patients were significantly younger, had significantly increased vaccine breakthrough rates, and were significantly less likely to be hospitalized. Omicron patients required less intense respiratory support and had a shorter length of hospital stay, consistent with on average decreased disease severity. Two patients with Omicron stealth sublineage BA.2 also were identified. The data document the unusually rapid spread and increased occurrence of COVID-19 caused by the Omicron variant in metropolitan Houston, Texas, and address the lack of information about disease character among US patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2022) · Nature · doi:10.1038/s41586-021-04385-3 · Cited by 2,006
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Liu, L., Iketani, S., Guo, Y., Chan, J. F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., et al. (2022) · Nature · doi:10.1038/s41586-021-04388-0 · Cited by 1,290
Wolter, N., Jassat, W., Walaza, S., Welch, R., Moultrie, H., Groome, M., Amoako, D. G., Everatt, J., Bhiman, J. N., Scheepers, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00017-4 · Cited by 1,041
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., Duyvesteyn, H. M. E., Ginn, H. M., Mentzer, A. J., Tuekprakhon, A., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.046 · Cited by 930
Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada
Ulloa, A. C., Buchan, S. A., Daneman, N., & Brown, K. A. (2022) · JAMA · doi:10.1001/jama.2022.2274 · Cited by 316
Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India
Dhar, M. S., Marwal, R., Radhakrishnan, V., Ponnusamy, K., Jolly, B., Bhoyar, R. C., Sardana, V., Naushin, S., Rophina, M., Mellan, T. A., et al. (2021) · doi:10.1101/2021.06.02.21258076 · Cited by 296
Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters
Yuan, S., Ye, Z.-W., Liang, R., Tang, K., Zhang, A. J., Lu, G., Ong, C. P., Man Poon, V. K., Chan, C. C.-S., Mok, B. W.-Y., et al. (2022) · Science · doi:10.1126/science.abn8939 · Cited by 191
Hansen, C. H., Schelde, A. B., Moustsen-Helm, I. R., Emborg, H.-D., Krause, T. G., Mølbak, K., & Valentiner-Branth, P. (2021) · doi:10.1101/2021.12.20.21267966 · Cited by 133
Cited by
Chatterjee, S., Bhattacharya, M., Nag, S., Dhama, K., & Chakraborty, C. (2023) · Viruses · doi:10.3390/v15010167 · Cited by 313
Modeling transmission of SARS-CoV-2 Omicron in China
Cai, J., Deng, X., Yang, J., Sun, K., Liu, H., Chen, Z., Peng, C., Chen, X., Wu, Q., Zou, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01855-7 · Cited by 281
The neurobiology of SARS-CoV-2 infection
Meinhardt, J., Streit, S., Dittmayer, C., Manitius, R. V., Radbruch, H., & Heppner, F. L. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-023-00769-8 · Cited by 64
Waning of SARS-CoV-2 vaccine-induced immunity: A systematic review and secondary data analysis
Menegale, F., Manica, M., Zardini, A., Guzzetta, G., Marziano, V., d’Andrea, V., Trentini, F., Ajelli, M., Poletti, P., & Merler, S. (2022) · doi:10.1101/2022.07.04.22277225 · Cited by 1
Metadata
- Authors
- Christensen, P. A., Olsen, R. J., Long, S. W., Snehal, R., Davis, J. J., Ojeda Saavedra, M., Reppond, K., Shyer, M. N., Cambric, J., Gadd, R., Thakur, R. M., Batajoo, A., Mangham, R., Pena, S., Trinh, T., Kinskey, J. C., Williams, G., Olson, R., Gollihar, J., & Musser, J. M.
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2022-04
- Volume
- 192
- Issue
- 4
- Pages
- 642-652
- ISSN
- 0002-9440 (ISSN-L)
- OpenAlex
- W4210585911
- Cited by
- 212
- References
- 9
- FWCI
- 23.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas. https://app.cochat.ai/papers/10.1016/j.ajpath.2022.01.007
- The paper
- Christensen, P. A., Olsen, R. J., Long, S. W., Snehal, R., Davis, J. J., Ojeda Saavedra, M., Reppond, K., Shyer, M. N., Cambric, J., Gadd, R., Thakur, R. M., Batajoo, A., Mangham, R., Pena, S., Trinh, T., Kinskey, J. C., Williams, G., Olson, R., Gollihar, J., & Musser, J. M. (2022). Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas. The American Journal of Pathology. https://doi.org/10.1016/j.ajpath.2022.01.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.